| AID1347412 | qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID604399 | Ratio of IC50 for CDK5/cyclinT to IC50 for CDK7/cyclinH/MAT1 | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
| A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration. |
| AID1651617 | Inhibition of CDK9 (unknown origin) | 2020 | Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
| CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success? |
| AID1283430 | Inhibition of CDK2/Cyclin E (unknown origin) expressed in sf9 cells using histone H1 as substrate in presence of [gamma33P]-ATP | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases. |
| AID1771855 | Growth inhibition of human BT-549 cells assessed as cell viability measured after 4 days by WST8 assay | 2021 | Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
| Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer. |
| AID1609445 | Competitive reversible inhibition of CDK7 (unknown origin) | 2019 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
| Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019). |
| AID1651613 | Inhibition of CDK2 (unknown origin) | 2020 | Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
| CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success? |
| AID1283431 | Inhibition of CDK1 (unknown origin) | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases. |
| AID1283433 | Inhibition of CDK5 (unknown origin) using histone H1 as substrate in presence of [gamma33P]-ATP | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases. |
| AID1283446 | Inhibition of CDK7 (unknown origin) | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases. |
| AID1651608 | Inhibition of CDK7 (unknown origin) | 2020 | Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
| CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success? |
| AID1651614 | Inhibition of CDK4 (unknown origin) | 2020 | Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
| CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success? |
| AID604398 | Ratio of IC50 for CDK4/cyclinD1 to IC50 for CDK7/cyclinH/MAT1 | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
| A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration. |
| AID605637 | Inhibition of CDK7/cyclinH/MAT1 assessed as amount of ATP released by luciferase activity based PKLight assay | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
| A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration. |
| AID1283429 | Inhibition of CDK4 (unknown origin) | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases. |
| AID1277156 | Inhibition of CDK1/Cyclin B (unknown origin) expressed in baculoviral infected insect Sf9 cells using histone H1 as substrate in presence of [gamma-33P]ATP | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors. |
| AID1651612 | Inhibition of CDK1 (unknown origin) | 2020 | Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
| CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success? |
| AID1609444 | Competitive reversible inhibition of CDK5 (unknown origin) | 2019 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
| Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019). |
| AID1277161 | Inhibition of CDK9/Cyclin T1 (unknown origin) using (YSPTSPS)2KK peptide as substrate in presence of [gamma-33P]ATP | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors. |
| AID1771856 | Growth inhibition of human MDA-MB-231 cells assessed as cell viability measured after 4 days by WST8 assay | 2021 | Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
| Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer. |
| AID1283447 | Inhibition of CDK9 (unknown origin) | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases. |
| AID604400 | Ratio of IC50 for CDK6/cyclinD1 to IC50 for CDK7/cyclinH/MAT1 | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
| A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration. |
| AID1771854 | Growth inhibition of human MDA-MB-468 cells assessed as cell viability measured after 4 days by WST8 assay | 2021 | Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
| Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer. |
| AID1277160 | Inhibition of CDK7/Cyclin H/MAT1 (unknown origin) using (YSPTSPS)2KK peptide as substrate in presence of [gamma-33P]ATP | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors. |
| AID1651615 | Inhibition of CDK5 (unknown origin) | 2020 | Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
| CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success? |
| AID1609441 | Competitive reversible inhibition of CDK6 (unknown origin) | 2019 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
| Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019). |
| AID605641 | Ratio of IC50 for CDK2/cyclinE to IC50 for CDK7/cyclinH/MAT1 | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
| A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration. |
| AID1609446 | Competitive reversible inhibition of CDK2 (unknown origin) | 2019 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
| Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019). |
| AID1277158 | Inhibition of CDK4/Cyclin D1 (unknown origin) using RPPTLSPIPHIPR peptide as substrate in presence of [gamma-33P]ATP | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors. |
| AID1609442 | Competitive reversible inhibition of CDK8 (unknown origin) | 2019 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
| Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019). |
| AID1277159 | Inhibition of CDK5/p35NCK (unknown origin) using histone H1 as substrate in presence of [gamma-33P]ATP | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors. |
| AID1651616 | Inhibition of CDK6 (unknown origin) | 2020 | Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
| CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success? |
| AID605640 | Ratio of IC50 for CDK1/cyclinB1 to IC50 for CDK7/cyclinH/MAT1 | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
| A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration. |
| AID1609443 | Competitive reversible inhibition of CDK4 (unknown origin) | 2019 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
| Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019). |
| AID1345612 | Human cyclin dependent kinase 2 (CDK1 subfamily) | 2009 | Cancer research, Aug-01, Volume: 69, Issue:15
| The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. |
| AID1345652 | Human cyclin dependent kinase 7 (CDK7 subfamily) | 2009 | Cancer research, Aug-01, Volume: 69, Issue:15
| The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |